Elzonris Approved for BPDCN and Sprycel Approval Expanded

Elzonris approved for BPDCN

The FDA has approved ElzonrisTM (tagraxofusp-erzs), a targeted therapy, for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and children over age 2. This is the first treatment approved for BPDCN and is a CD123-directed cytotoxin. BPDCN is a rare hematologic cancer that often progresses into acute leukemia.1,2

Prior to this approval, most individuals with BPDCN received the standard of care regimen of chemotherapy followed by a stem cell transplant. BPCDN predominantly impacts older patients who may not be able to tolerate such an intensive treatment regimen.2 Elzonris represents a new option for people with BPDCN.

Sprycel pediatric indication expanded

The FDA recently expanded its approval for the targeted therapy Sprycel® (dasatinib) in combination with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in children over 1 year.3 ALL is a common childhood cancer and is more common in children than adults, with the greatest risk in children aged 5 and younger.4

Sprycel had previously been approved for several indications, including newly diagnosed and chronic, accelerated, myeloid or lymphoid Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in adults, refractive Ph+ ALL in adults, and refractive Ph+ CML in pediatric patients.3

By providing your email address, you are agreeing to our privacy policy.

This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The Blood-Cancer.com team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.

Join the conversation

or create an account to comment.

Community Poll

Have you met another blood cancer patient?